Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial.

By R. Bailey, S. Moses, C. Parker, K. Agot, I. Maclean, J. Krieger, C. Williams, R. Campbell, J. Ndinya‐Achola. The Lancet, 2007

2,210 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

An effect size primer: A guide for clinicians and researchers. (2009, background): “A recent clinical trial of circumcision used to prevent HIV among Kenyan men found that of 1,391 men randomized to circumcision, 22 later had HIV, whereas 47 in the control uncircumcised group of 1,393 became HIV positive (Bailey et al., 2007).”
Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women (2010, positive): “The successful trials tested medical male circumcision in South Africa (4), Kenya (5), and Uganda (6) (combined effectiveness in reducing HIV acquisition was 57%), sexually transmitted infection (STI) treatment in Tanzania (effectiveness in reducing HIVacquisition was 42”
Estimating per-act HIV transmission risk: a systematic review (2014, neutral): “circumcision [75–80].”